
Radiation Oncologist at Ospedale Isola Tiberina - Gemelli Isola #radonc
Joined October 2011
- Tweets4.5K
- Following1.6K
- Followers994
- Likes1.4K
Calogero Casà, MD, MSc, PhD retweeted
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112
@UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
Calogero Casà, MD, MSc, PhD retweeted
Proud of our growing radiation oncology community and its commitment @ESTRO_RT See you all in Milano 🎤🩺💫☕️🇮🇹
You did it again! 🚀 A new record for #ESTRO27: abstract submission closed yesterday with 4,585 abstracts, up 12% on last year and the 4th record year in a row!
🙏 Thank you for advancing radiation oncology and cancer care research.
See you in Milan! ✨
Calogero Casà, MD, MSc, PhD retweeted
🧬 Are we underestimating rare prostate cancer histologies simply because we rarely look for them?
nature.com/articles/s41585-0…
Rare prostate cancer histologies: detection, characteristics and treatment
Rare #ProstateCancer histologies comprise less than 5% of cases but represent a clinically important and under-recognized group.
➡️These subtypes often show aggressive behaviour, atypical metastatic patterns and poorer outcomes, while remaining underrepresented in guidelines and trials.
➡️Accurate diagnosis increasingly depends on multiparametric MRI, immunohistochemistry and genomic profiling.
➡️Molecular alterations such as DNA🧬 repair defects, TP53/RB1 loss and mismatch repair deficiency may offer therapeutic opportunities, highlighting the need for subtype-specific evidence and prospective studies.
@bavilima , @UrogerliMD, @katcollmd, @neerajaiims, @PGrivasMDPhD, @Albert0Briganti, @AndreaNecchi, @LiangChengMD, @SpiessPhilippe
@Oncoalert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Calogero Casà, MD, MSc, PhD retweeted
Darolutamide with ADT and locoregional
radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest staging with PSMA-PET changes things #ESMO26 @Silke_Gillessen @ChrisSweens1
Calogero Casà, MD, MSc, PhD retweeted
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
Calogero Casà, MD, MSc, PhD retweeted
Importantly this is modern data that with a spacer gel and SBRT at 2 years 80% of men remain potent.
This is in a prospective RCT with patient reported outcomes.
🧐nerve-sparing prostate RT?
@ndesai2005 presents Poten-C trial
Unilateral NVB sparing:
❌ did not improve sexual function (primary endpoint)
🤔 urinary function better w NVB sparing
@ASTRO_org #ASTRO26
Calogero Casà, MD, MSc, PhD retweeted
Accela, the new linac from Varian @SiemensHealth
cancercare.siemens-healthine…
Calogero Casà, MD, MSc, PhD retweeted
Replying to @piet_ost @PaulSargos
Likely I agree. Even in RADICALS G3 events are higher than de novo radiotherapy. Best to only operate if you have a good chance of cure, otherwise the patient may need two sets of side effects to achieve cure
Calogero Casà, MD, MSc, PhD retweeted
SBRT to pelvis and prostate with 1y of ADT has a 91% freedom from biochemical failure. pmc.ncbi.nlm.nih.gov/article…
For RP it’s 22%.
Can you see a difference?
🚨 Is surgery alone enough for today’s highest-risk prostate cancer patients?
Article 📰
sciencedirect.com/science/ar…
Oncologic Outcomes in a Contemporary “PROTEUS-like” Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy
A retrospective cohort of 1,392 patients with PROTEUS-like high-risk #ProstateCancer undergoing radical prostatectomy without neoadjuvant therapy 🧪 demonstrates substantial long-term disease recurrence and progression.
Biochemical recurrence-free survival declined 📉 from 60% at 3 years to 22% at 10 years, while metastasis-free survival fell to 56%. Cancer-specific survival remained relatively high.
✅ These findings highlight persistent unmet needs and support prospective evaluation of perioperative treatment intensification strategies such as apalutamide plus androgen deprivation therapy.
@jcasusce , @JSteinestel , @RomanMayr , @matheck , @TWesthofen
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Calogero Casà, MD, MSc, PhD retweeted
🧬 When precision medicine gives you two different answers, which one do you trust? A CLINICAL CASE
Article 📰
acsjournals.onlinelibrary.wi…
Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer 🩺 (Virtual Tumor Board)
A clinical case highlights the challenge of discordant precision biomarkers 🎯 in unfavorable intermediate-risk localized #ProstateCancer . Decipher indicated high genomic 🧬 risk and potential benefit from treatment intensification, while ArteraAI predicted low metastatic risk and minimal benefit from short-term ADT.
✅ The authors emphasize distinguishing prognostic from predictive biomarkers and recommend multidisciplinary interpretation, shared decision-making, and adherence to evidence-based guidelines until prospective studies establish how conflicting biomarker results should guide therapy.
@ShalinJShahMD
@KHoffmanMD
@sumit_subudhi
@CurtisPettaway1
@ChadTangMD
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Calogero Casà, MD, MSc, PhD retweeted
💡always a priviledge to witness @montypal lectures on kidney cancer!
🔬🧬 variant histologies undoubtedly represent a constant challenge for the most appropriate systemic approach to be selected ...not that much after Monty's talk!
#GUCancersFocusMeeting🇺🇸 – at Boston, MA
Calogero Casà, MD, MSc, PhD retweeted
🧬 Capivasertib + abiraterone offers a precision-medicine alternative to chemotherapy-based triplet therapy in PTEN-deficient metastatic APMN/S prostate cancer.
At #USPCC26, Dr. Russell Szmulewitz @UChicagoMed highlighted CAPItello-281: in 1,012 patients with PTEN-deficient de novo metastatic disease, capivasertib improved median rPFS from 25.7 to 33.2 months, with the largest apparent benefit in complete PTEN loss. OS is still immature, while toxicity—including diarrhea, hyperglycemia, rash, and anemia—was manageable but led to discontinuation in ~18%.
Bottom line: For high-volume, de novo PTEN-deficient disease, capivasertib + abiraterone targets a poor-prognosis biology at the earliest opportunity—without requiring docetaxel.
Written coverage by @zklaassen_md on UroToday > bit.ly/4wdPyHk
Calogero Casà, MD, MSc, PhD retweeted
Excited to share our new @EORTC publication in European Urology describing the design of the EORTC 2238 DE-ESCALATE trial.
Can intermittent maximal androgen blockade reduce treatment burden while maintaining outcomes in selected men with #mHSPC receiving ADT + ARPI? That's the question we're addressing.
👉 doi.org/10.1016/j.eururo.202…
@DeEscalate_EU #ProstateCancer #ClinicalTrials #EUrology
Calogero Casà, MD, MSc, PhD retweeted
🧵 The 10-year FLAME results are important data, and one sentence in Methods deserves more attention than the headline bDFS numbers: “No additional toxicity outcomes were collected after 60 months.” A thread on what that means for a treatment now entered into standard practice
Calogero Casà, MD, MSc, PhD retweeted
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
thelancet.com/journals/lanon…
The phase 2 ARTO trial evaluated whether adding stereotactic body radiotherapy (SBRT) ☢️ as metastasis-directed therapy to abiraterone 💊 plus androgen deprivation therapy improves outcomes in patients with oligometastatic castration-resistant #ProstateCancer .
After a median follow-up of 53 months, combination therapy significantly improved overall survival (HR 0.55), with median survival not yet reached versus 50 months in the control arm. Toxicity remained manageable, supporting MDT as an effective strategy alongside systemic therapy in this setting.
@BarbaraJereczek
@ChadTangMD
@GiulioFrancoli1
@PierluigiBonomo
@Ric_Campi
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists
Calogero Casà, MD, MSc, PhD retweeted
Ivy Brain Tumor Center announces completion of enrollment of its Phase 3 Gliofocus Study. 450 pts were randomized to receive niraparib or temozolomide anf RT using the @ESTRO_RT @EANOassociation guidelines followed by adjuvant niraparib or temozolomide.
@IvyBrainTumCtr
Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM - Giuseppe Minniti
@gminniti2012 @IvyBrainTumCtr @ESTRO_RT
oncodaily.com/voices/giusepp…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews @CancerWorldmag
Calogero Casà, MD, MSc, PhD retweeted
🏆 Proud that our #RADIOSA post-hoc analysis was ranked among the top 5% of all abstracts submitted to #ESTRO2026. A great recognition for an incredible team effort. Thank you to all collaborators and patients who made this possible! #RadOnc #PCa #MDT
Calogero Casà, MD, MSc, PhD retweeted
📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled “Circulating Tumour DNA Positivity Predicts Shorter Survival for Patients with High-grade pT1 Urothelial Bladder Carcinoma”.
👏 Congratulations to Faisal Bin Humaid, Goel A., and Bryan R. on this excellent contribution, together with all co-authors.
🔗 Read the full article here:
👉 buff.ly/WsWATaZ
#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology
Calogero Casà, MD, MSc, PhD retweeted
“Rebranding radiation oncology” is not about changing a name, it is about redefining our role in modern oncology.
We don’t just deliver technology. We cure patients.
Precision. Evidence. Collaboration.
Excellent lecture by @BarbaraJereczek on ESTRO’s vision for the future of RT.



















































